United Kingdom (UK)
Recombinant monoclonal antibody to E protein. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the hybridoma Mab 4.2.
UniProt Accession Number of Target Protein: P14336; P22338
Alternative Name(s) of Target: tick-borne encephalitis virus; TBEV; LIV; Envelope protein Domain III
Specificity: This antibody binds to the lateral ridge of domain III of the E protein (EDIII) of LIV or TBEV, an epitope also reported for other potently neutralizing monoclonal antibodies against mosquito-borne flaviviruses (MBFVs), but adopts a unique binding orientation. Tick-borne encephalitis virus (TBEV) and louping ill virus (LIV) are members of the tick-borne flaviviruses (TBFVs) in the family Flaviviridae which cause encephalomeningitis and encephalitis in humans and other animals. The antibody reacts also with Negishi virus and Turkish sheep encephalomyelitis virus.
Application Notes: The antibody prevented mice against challenge with a lethal dose of LIV (Gao et al., 1994; PMID: 8126456). The specificity of the scFv fragment for LIV antigen was confirmed by ELISA analysis. Immunofluorescence was performed on PS cells infected with LIV or TBEV using the scFv and the original antibody. The antibody and the scFv fragment could neutralize both LIV and TBEV (Jiang et al., 1994; PMID: 8128623). The binding affinities of the scFv fragment for LIV E and for TBEV E were measured by surface plasmon resonance (respectively 45.4 nM and 390 nM for LIV and TBEV E). The structures of the scFv fragment in complex with the envelope protein from either TBEV or LIV were determined. The antibody showed potential as a therapeutic agent (Yang et al., 2019; PMID: 30760569).
Antibody first published in:
Venugopal et al. Nucleotide sequence of the envelope glycoprotein of Negishi virus shows very close homology to louping ill virus Virology. 1992 Sep;190(1):515-21. PMID:1326816
Note on publication:
The paper describes the generation and characterization of the antibody.